ZYVERSA THERAPEUTICS

ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs for patients with inflammatory or kidney diseases with high unmet medical needs. We are well positioned in the rapidly emerging inflammasome space with a highly differentiated inflammasome inhibitor (IC 100), and in kidney disease with a novel phase 2a-ready cholesterol efflux mediator (VAR 200). Lead products in each therapeutic area offer a "pipeline within a product," with potential for numerous indications. The total accessible market is over $70 billion. 1,2... ZyVersa is committed to improving health outcomes and quality of life for patients with inflammatory and renal diseases

Also known as: ZyVersa, ZyVersa Therapeutics, Inc.

Primary location: Weston United States